



CHEMESIS INTERNATIONAL INC.

**Condensed Consolidated Interim Financial Statements
For the three and six months ended December 31, 2020 and 2019**

NOTICE TO READER

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that the condensed consolidated interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of Chemesis International Inc. (the “Company”) have been prepared by and are the responsibility of management. These condensed consolidated interim financial statements for the three and six months ended December 31, 2020 has not been reviewed or audited by the Company’s independent auditors. All amounts are stated in Canadian Dollars unless otherwise stated.

Chemesis International Inc.
Condensed Consolidated Interim Statements of Financial Position
(Expressed in Canadian dollars)

As at	December 31, 2020 (Unaudited)		June 30, 2020
ASSETS			
Current assets			
Cash	\$	230,199	\$ 185,279
Amounts receivable (Note 13)		96,104	79,544
Prepaid expenses and deposits		10,118	10,118
Assets held for sale (Note 5)		-	4,540,947
Inventory (Note 8)		7,922	38,506
		344,343	4,854,394
Non-current assets			
Assets held for sale (Note 5)		-	17,332,726
Fixed assets (Note 11)		194,711	201,335
Intangible assets (Note 9)		34,476	51,143
Total non-current assets		229,187	17,585,204
TOTAL ASSETS	\$	573,530	\$ 22,439,598
LIABILITIES			
Current			
Accounts payable and accrued liabilities (Note 15)	\$	2,080,722	\$ 2,748,962
Income tax payable		-	76,974
Convertible debt (Note 12)		916,245	1,063,562
Liabilities held for sale (Note 5)		-	4,615,960
		2,996,967	8,505,080
Non-current liabilities			
Liabilities held for sale (Note 5)		-	2,096,778
		-	2,096,778
TOTAL LIABILITIES	\$	2,996,967	\$ 10,602,236
EQUITY			
Share capital (Note 14)		80,989,920	77,952,340
Subscriptions received		100,000	22,500
Contributed surplus		5,704,365	5,814,928
Accumulated other comprehensive income		306,975	240,078
Deficit		(89,737,626)	(76,517,929)
Equity attributable to shareholders of Chemesis		(2,636,366)	7,511,917
Non-controlling interests (Note 10)		212,929	4,325,445
TOTAL EQUITY		(2,423,437)	11,837,362
TOTAL LIABILITIES AND EQUITY	\$	573,530	\$ 22,439,598
Subsequent events (Note 24)	Contingent liabilities (Note 22)		
Going concern (Note 2)			

Approved on behalf of the Board of Directors:

"Brian Thurston", Director

"Aman Parmar", Director

The accompanying notes are an integral part of these consolidated financial statements.

Chemesis International Inc.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Expressed in Canadian dollars)

(Unaudited)	For the three months ended		For the six months ended	
	December 31, 2020	December 31, 2019 (Restated)	December 31, 2020	December 31, 2019 (Restated)
REVENUES	\$ -	\$ 178,789	\$ -	\$ 543,303
COST OF GOODS SOLD (Note 8)	-	(170,118)	-	(516,953)
GROSS PROFIT	-	8,671	-	26,350
EXPENSES				
Depreciation (Notes 11)	10,571	1,519,165	23,292	1,701,272
Foreign exchange loss (gain)	(4,350)	(251,588)	(9,779)	(256,847)
General and administration (Note 16 and 17)	1,703,172	2,853,662	3,264,763	4,132,487
Share-based payments (Notes 14 and 15)	-	189,208	-	261,840
TOTAL OPERATING EXPENSES	(1,709,393)	(4,310,447)	(3,278,276)	(5,838,752)
LOSS BEFORE OTHER ITEMS	(1,709,393)	(4,301,776)	(3,278,276)	(5,812,402)
OTHER ITEMS:				
Interest expense	71,025	16,250	(116,175)	(60,647)
Impairment	-	-	-	-
Loss on sale of building	-	(3,441,692)	-	(3,441,692)
Loss on investment in GSRX Industries Inc.	-	(8,743,848)	-	(10,308,227)
	71,025	(12,169,290)	(116,175)	(13,810,566)
NET LOSS BEFORE DISCONTINUED OPERATIONS AND INCOME TAXES	(1,638,368)	(16,471,066)	(3,394,451)	(19,622,968)
Income (loss) on discontinued operations, net of tax (Note 5)	(11,188,597)	220,465	(14,061,599)	(343,674)
Income tax recovery (expense)	-	-	-	133,000
NET LOSS	(12,826,965)	(16,250,601)	(17,456,050)	(19,833,642)
OTHER COMPREHENSIVE INCOME (LOSS)				
Cumulative translation adjustment, attributable to:				
Continuing operations	120,189	282,198	93,293	(663,170)
Discontinued operations	(293,544)	(272,198)	97,441	332,239
COMPREHENSIVE LOSS	\$ (13,000,320)	\$ (16,240,601)	\$ (17,265,316)	\$ (20,164,573)
NET LOSS ATTRIBUTABLE TO:				
Chemesis International Inc.	(9,564,057)	(15,419,550)	(10,417,630)	(19,091,276)
Discontinued operations	70,934	(670,225)	(2,802,068)	(534,364)
Non-controlling interests	(3,333,842)	(160,826)	(4,236,352)	(208,002)
NET LOSS	\$ (12,826,965)	\$ (16,250,601)	\$ (17,456,050)	\$ (19,833,642)
COMPREHENSIVE LOSS ATTRIBUTABLE TO:				
Chemesis International Inc.	(7,085,927)	(16,858,403)	(10,324,337)	(20,673,219)
Discontinued operations	(2,675,612)	617,802	(2,704,627)	332,239
Non-controlling interests	(3,238,781)	-	(4,236,352)	176,407
COMPREHENSIVE LOSS	\$ (13,000,320)	\$ (16,240,601)	\$ (17,265,316)	\$ (20,164,573)
Loss per share, basic and diluted	\$ (0.32)	\$ (1.55)	\$ (0.45)	\$ (1.97)
Loss per share, basic and diluted, continuing operations	\$ (0.32)	\$ (1.49)	\$ (0.37)	\$ (1.92)
Loss per share, basic and diluted, discontinued operations	\$ 0.00	\$ (0.06)	\$ (0.07)	\$ (0.05)
Weighted average number of common shares outstanding	40,127,172	10,482,452	38,699,748	10,072,976

The accompanying notes are an integral part of these consolidated financial statements.

Chemesis International Inc.
Consolidated Statements of Changes in Equity
(Expressed in Canadian dollars)

	<u>Share Capital</u>		Subscriptions received	Contributed surplus	Accumulated other comprehensive income (loss)	Deficit	Equity attributable to shareholders of Chemesis	Non-controlling interests	Total equity
	Number	Amount							
	\$	\$	\$	\$	\$	\$	\$	\$	\$
As at June 30, 2020	33,891,694	77,952,340	22,500	5,814,928	240,078	(76,517,929)	7,511,917	4,325,445	11,837,362
Shares issued for cash	2,542,800	1,271,400	(22,500)	-	-	-	1,248,900	-	1,248,900
Conversion of RSUs into common shares	125,000	110,563	-	(110,563)	-	-	-	-	-
Exercise of warrants	2,573,431	1,042,240	-	-	-	-	1,042,240	-	1,042,240
Shares for debt	1,044,036	613,377	-	-	-	-	613,377	-	613,377
Subscriptions received	-	-	100,000	-	-	-	100,000	-	100,000
Net loss	-	-	-	-	-	(13,219,698)	(13,219,698)	(4,236,352)	(17,456,050)
Other comprehensive income	-	-	-	-	66,898	-	66,898	123,836	190,734
As at December 31, 2020	40,176,961	80,989,920	100,000	5,704,365	306,976	(89,737,627)	(2,636,366)	212,929	(2,423,437)

The accompanying notes are an integral part of these consolidated financial statements.

Chemesis International Inc.
Consolidated Statements of Changes in Equity
(Expressed in Canadian dollars)

	<u>Share Capital</u>		Subscriptions received	Contributed surplus	Accumulated other comprehensive income (loss)	Deficit	Equity attributable to shareholders of Chemesis	Non-controlling interests	Total equity
	Number	Amount							
		\$							
As at June 30, 2019 (Restated- Note 28)	9,216,353	56,954,958	-	5,067,327	569,066	(39,527,486)	23,063,865	258,771	23,322,636
Acquisition of GSRX common shares	1,488,071	8,437,358	-	-	-	-	8,437,358	4,811,232	13,248,590
Shares held internally	(729,187)	(6,027,801)	-	-	-	-	(6,027,801)	-	(6,027,801)
Acquisition of SAP	100,000	1,780,000	-	(2,602,879)	118,094	-	(704,785)	704,785	-
Acquisition of GSRX preferred shares	400,000	1,840,000	-	-	(1,840,000)	-	-	-	-
Shares issued for intangible asset	15,750	269,316	-	-	-	-	269,316	-	269,316
Shares issued to settle note payable	60,000	732,000	-	-	-	-	732,000	-	732,000
Private placements, net	77,703	575,000	-	-	-	-	575,000	-	575,000
Subscriptions received	-	-	743,500	-	-	-	743,500	-	743,500
Shares issued for options exercised	10,000	248,000	-	(108,000)	-	-	140,000	-	140,000
Shares issued for services	30,938	57,235	-	-	-	-	57,235	-	57,235
Issuance of shares by GSRX for services	-	-	-	(85,285)	-	-	(85,285)	111,109	25,824
Share-based payments	-	-	-	180,003	-	-	180,003	-	180,003
Net loss	-	-	-	-	-	(20,294,491)	(20,294,491)	(208,002)	(20,502,493)
Other comprehensive loss	-	-	-	-	(111,180)	-	(111,180)	(189,397)	(300,577)
As at December 31, 2019 (Restated – Note 28)	10,669,628	64,866,066	743,500	2,451,166	(1,264,020)	(59,821,977)	6,974,735	5,488,498	12,463,233

The accompanying notes are an integral part of these consolidated financial statements.

Chemesis International Inc.
Consolidated Statements of Changes in Equity
(Expressed in Canadian dollars)

	<u>Share Capital</u>		Subscriptions received	Contributed surplus	Accumulated other comprehensive income (loss)	Deficit	Equity attributable to		Total equity
	Number	Amount					shareholders of Chemesis	Non-controlling interests	
		\$	\$	\$	\$	\$	\$	\$	\$
As at January 1, 2020 (Restated – Note 28)	10,669,628	64,866,066	743,500	2,451,166	(1,264,020)	(59,821,977)	6,974,735	5,488,498	12,463,233
Acquisition of GSRX preferred shares	-	428,000	-	-	1,840,000	-	2,268,000	-	2,268,000
Shares issued to settle liabilities	1,621,684	1,337,828	-	-	-	-	1,337,828	-	1,337,828
Convertible debt	8,072,054	6,649,269	-	-	-	-	6,649,269	-	6,649,269
Private placements, net	13,528,328	4,671,177	-	-	-	-	4,671,177	-	4,671,177
Subscriptions received	-	-	(721,000)	-	-	-	(721,000)	-	(721,000)
Share-based payments	-	-	-	3,363,762	-	-	3,363,762	-	3,363,762
Net loss	-	-	-	-	-	(16,695,952)	(16,695,952)	(1,420,032)	(18,115,984)
Other comprehensive loss	-	-	-	-	(335,902)	-	(335,902)	256,979	(78,923)
As at June 30, 2020	33,891,694	77,952,340	22,500	5,814,928	240,078	(76,517,929)	7,511,917	4,325,445	11,837,362

The accompanying notes are an integral part of these consolidated financial statements.

Chemesis International Inc.
Consolidated Statements of Cash Flows
(Expressed in Canadian dollars)

For the six months ended December 31	2020		2019	
Cash (used in) provided by:				
OPERATING ACTIVITIES				
Net loss from continuing operations	\$	(10,417,630)	\$	(19,091,276)
Net loss from non-controlling interests		(4,236,352)		(534,364)
Net loss from discontinued operations		(2,802,068)		(208,002)
	\$	(17,456,050)	\$	(19,833,642)
Items not involving cash:				
Share-based payments		-		199,666
Change in fair value of embedded derivative liabilities		-		(2,611,504)
Interest/accretion		116,175		589,040
Impairment of assets		(256,867)		3,441,692
Depreciation		12,721		2,620,743
Gain on disposal of assets		-		(256,610)
Net changes in non-cash working capital items:				
Prepaid expenses and deposits		-		-
Inventory		30,584		(348,894)
Biological assets		-		829,717
Income tax payable		(76,974)		(133,000)
Unearned revenue		-		-
Net assets held for sale		15,351,668		10,013,401
Amounts receivable		(16,560)		1,446,465
Amounts payable and other payables		(50,917)		(1,840,127)
Net cash used in operating activities		(2,346,220)		(5,883,053)
INVESTING ACTIVITIES:				
Deposit		-		(223,319)
Proceeds received on sale of building		-		1,254,626
Acquisition of GSRX		-		2,074,166
Purchase of equipment and leasehold improvements		-		(730,580)
Net cash provided by (used in) investing activities		-		2,374,893
FINANCING ACTIVITIES:				
Proceeds from private placement, net		1,271,400		575,000
Proceeds from convertible debt		-		1,462,190
Proceeds from warrant exercise		1,042,240		140,000
Subscriptions received		77,500		743,500
Net cash provided by financing activities		2,391,140		2,920,690
Effect of exchange rate changes on cash		-		-
Net increase (decrease) in cash		44,920		(587,470)
Cash, beginning of year		185,279		641,583
Cash, end of period	\$	230,199	\$	54,113

Non-cash investing and financing activities - See Note 18
The accompanying notes are an integral part of these consolidated financial statements.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

1. NATURE OF OPERATIONS

Chemesis International Inc. (“Chemesis” or “the Company”) was incorporated under the Business Corporations Act of British Columbia on April 26, 2013. Chemesis’ registered records office is 2200 HSBC Building, 885 West Georgia Street, Vancouver BC V6C 3E8 and the corporate head office is at 2710 – 200 Granville Street, Vancouver, BC V6C 1S4. The Company trades on the Canadian Securities Exchange (“CSE”) under the symbol CSI, on the OTC markets under the symbol CADMF, and on the Frankfurt Stock Exchange under the symbol CWAA.

During November 2020, the company entered into sale agreements with Puerto Rico Industrial Commercial Holdings Biotech Corp, for the sale of Natural Ventures Puerto Rico and all of the Puerto Rican assets of GSRX. Accordingly, the related assets and liabilities have been presented separately on the statement of financial position as at December 31, 2020 and June 30, 2020. Additionally, the sum of the post-tax loss of the discontinued operations and post-tax gain or loss recognized on the measurement to fair value less cost to sell or fair value adjustments on the disposal of the assets has been presented as a single amount on the face of the statement of comprehensive income for the six months ended December 31, 2020 and 2019.

2. GOING CONCERN

These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due. Management is aware, in making its assessment, of material uncertainties related to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern. During the six months ended December 31, 2020, the Company incurred a loss of \$17,456,050 and as at December 31, 2020 has a working capital deficit of \$2,652,624 and an accumulated deficit of \$89,737,626 and remains dependent upon the receipt of additional equity or debt financing. While management has been successful in obtaining required financing in the past, there is no assurance that additional financing will be available or be available on favourable terms. The Company’s ability to continue as a going concern is dependent upon the ability to raise financing and ultimately generate profitable operations. These consolidated financial statements do not reflect and adjustments to the carrying value of assets and liabilities and the reported amounts of expenses and statement of financial position classifications that would be necessary if the going concern assumption was not appropriate. Such adjustments could be material.

In the United States, 33 states, the District of Columbia, and four U.S. territories allow the use of medical cannabis. Alaska, California, Colorado, Maine, Massachusetts, Nevada, Oregon, Washington, Vermont and the District of Columbia legalized the sale and adult-use of recreational cannabis.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

2. GOING CONCERN (CONTINUED)

At the federal level, however, cannabis currently remains a Schedule I controlled substance under the Federal Controlled Substances Act of 1970 (“Federal CSA”). Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. As such, even in those states in which marijuana is legalized under state law, the manufacture, importation, possession, use or distribution of cannabis remains illegal under U.S. federal law. This has created a dichotomy between state and federal law, whereby many states have elected to regulate and remove state-level penalties regarding a substance which is still illegal at the federal level.

There remains uncertainty about the US federal government’s position on cannabis with respect to cannabis-legal states. A change in its enforcement policies could also impact the ability of the Company to continue as a going concern.

In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period.

3. BASIS OF PRESENTATION

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (“IAS”) 34 “Interim Financial Reporting”. They do not include all of the information required for full annual financial statements and should be read in conjunction with the Company's audited annual consolidated financial statements for the fiscal year ended June 30, 2020, filed October 28, 2020, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”).

The condensed consolidated interim financial statements were authorized for issue in accordance with a resolution from the Board of Directors on March 1, 2020.

These consolidated financial statements have been prepared on a historical cost basis. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. The accounting policies below have been applied to all periods presented in these consolidated financial statements and are based on International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations of the International Financial Reporting Interpretation Committee (“IFRIC”).

3.1. Basis of measurement

These consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments that are measured at fair value. All amounts are presented in Canadian dollars unless otherwise specified.

3.2. Significant judgments, estimates and assumptions

The preparation of the Company’s consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are continually evaluated and are based on management’s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

3. BASIS OF PRESENTATION (CONTINUED)

Critical Accounting Judgments

The assumption that the Company will be able to continue as a going concern is subject to critical judgments by management with respect to assumptions surrounding the short and long-term operating budget, expected profitability, investing and financing activities and management's strategic planning. Should those judgments prove to be inaccurate, management's continued use of the going concern assumption could be inappropriate.

Going concern

The assessment of the Company's ongoing viability as an operating entity and determination of the related disclosures require significant judgment. In assessing the Company's ability to continue as a going concern, market and regulatory factors are considered.

Business combinations

Judgment is used when determining whether an acquisition is a business combination or an asset acquisition. Judgment is also used in measuring the fair value of equity instruments issued as consideration for a business combination, and in allocating the fair value of consideration paid to the assets acquired and liabilities assumed.

The Company measures all assets acquired and liabilities assumed at their acquisition-date fair values. Non-controlling interests in the acquiree are measured on the basis of the non-controlling interests' proportionate share of this equity in the acquiree's identifiable net assets. The excess of the aggregate of the consideration transferred and the amount of any non-controlling interests in the acquiree over the net assets of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed, is recognized as goodwill as of the acquisition date.

Functional currency

Determination of an entity's functional currency involves judgment taking into account the transactions, events, and conditions relevant to the entity. Determination of functional currency involves evaluating evidence about the primary economic environment in which the entity operations and is re-evaluated when facts and circumstances indicate that conditions have changed.

Collectability of amounts receivable

The Company monitors its exposure for credit losses on its customer and related party receivable balances and the creditworthiness of the customers and related parties on an ongoing basis and records related allowances for doubtful accounts. Allowances are estimated based upon specific customer and related party balances, where a risk of default is identified, and also include a provision for non-customer specific defaults based upon historical experience and aging of accounts.

Leases

Judgement is used when determining if the exercise of a lease renewal option is reasonably certain.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

3. BASIS OF PRESENTATION (CONTINUED)

Financial instruments

The determination of categories of financial assets and liabilities has been identified as an accounting policy which involves judgments or assessments made by management.

The identification of convertible note component is based on interpretations of the substance of the contractual arrangement and therefore requires judgement from management. The separation of components affects the initial recognition of the convertible debenture at issuance and the subsequent recognition of interest of the liability component. The determination of fair value of the liability is also based on several assumptions, including contractual future cash flows, discount rates and the presence of any derivative financial instruments.

Critical Accounting Estimates

Biological assets

Determination of the fair value of biological assets requires the Company to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, sales prices, wastage and expected yields of the cannabis plant. In determining final inventory value, the Company estimates obsolete or slow-moving inventory in determining net realizable value.

The Company's estimates are, by their nature, subject to change and differences from such change will be reflected in the gain or loss on biological assets in future periods.

Inventory

The Company estimates the net realizable value of inventory taking into account the most reliable evidence available at each reporting date.

Share-based payments

Where applicable, the fair value of certain equity instruments is subject to the limitations of the Black-Scholes option pricing model, as well as other pricing models that incorporate market data and involves uncertainty in estimates used by management in the assumptions. Because option pricing models require inputs of highly subjective assumptions, including the volatility of share prices, changes in subjective input assumptions can materially affect the fair value estimate.

Income Taxes

The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. While income tax filings are subject to audits and reassessments, the Company has adequately provided for all income tax obligations. However, changes in facts and circumstances as a result of income tax audits, reassessments, jurisprudence and any new legislation may result in an increase or decrease in our provision for income taxes.

Valuation of equity consideration granted

The valuation of share consideration granted involves management judgment in determining valuation of the share consideration granted. Judgment is exercised in the reliability of the fair value of consideration received.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

3. BASIS OF PRESENTATION (CONTINUED)

Estimated useful lives, impairment considerations and amortization of tangible assets, intangible assets, and goodwill

Amortization of tangible and intangible assets is dependent upon estimates of useful lives based on management’s judgment.

Goodwill impairment testing requires management to make critical estimates within the impairment testing model. On an annual basis, the Company tests whether goodwill is impaired.

Impairment of tangible and intangible assets with limited lives are affected by judgments about impairment indicators and estimates used to measure impairment losses where necessary.

The recoverable value of goodwill and tangible and intangible assets is determined using discounted cash flow models, which incorporate assumptions about future events including future cash flows, growth rates and discount rates.

3.3 Basis of consolidation

These consolidated financials are presented in Canadian dollars (“CAD”) and incorporate the financial results of the Company and its controlled subsidiaries:

Entity	Country	Functional currency	Ownership %
Chemesis International Inc.	Canada	CAD	Parent
1145411 BC Ltd. (“1145411”)	Canada	CAD	100%
Desert Zen LLC (“Desert Zen”)	USA - California	US dollar (“USD”)	100%
10998451 Canada Inc.	Canada	CAD	100%
Kieley Growth Management LLC (“Kieley”)	USA - California	USD	60%
La Finca Interactiva Arachna Inc. SAS. (La Finca”)	Colombia	Colombian Peso	100%
Bonhomie Labs LLC (“Bonhomie”)	USA - California	USD	100%
SAP Global Inc. (“SAP Global”)	USA - California	USD	100%
GSRX Industries Inc. (“GSRX”)*	USA	USD	66%

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

3. BASIS OF PRESENTATION (CONTINUED)

*List of subsidiaries and percentage of ownership held under GSRX includes the following:

Subsidiaries held by GSRX	Country	GSRX Ownership %
Andalucia 511, LLC;	USA	100%
Spirulinex, LLC;	USA	51%
Sunset Connect Oakland, LLC;	USA	55%
Green Spirit Essentials, LLC;	USA	55%
Green Spirit Mendocino, LLC;	USA	100%
138 Main Street PA, LLC.	USA	100%
GSRX SUPES, LLC	USA	100%
Point Arena Supply Co., LLC	USA	100%
Ukiah Supply Company, LLC	USA	100%
Pure and Natural, LLC	USA	100%
Point Arena Manufacturing, LLC	USA	94%
Point Arena Distribution, LLC	USA	100%
Pure and Natural-Lakeway, LLC	USA	51%
Pure and Natural One-TN, LLC	USA	51%
Green Room Palm Springs, LLC	USA	95%

Control exists when the parent company has the power, directly or indirectly, to govern the financial and operating policies of an entity to obtain benefits from its activities. The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany transactions and balances have been eliminated.

3.4 Non-controlling interests

Where the Company's interest is less than 100%, the interest attributable to outside shareholders is reflected in non-controlling interests. Non-controlling interests in the net assets of consolidated subsidiaries are identified separately from the Company's equity therein, and are initially recognized at the pro-rata share of ownership of the Company's net identifiable assets. Non-controlling interests consist of the amount of those interests at the date of the original business combination and the non-controlling interests' share of changes in equity since the date of the combination. See Note 11 for non-controlling interests' disclosures.

4. SIGNIFICANT ACCOUNTING POLICIES

These condensed consolidated interim financial statements have been prepared on the basis of accounting policies and methods of computation consistent with those applied in the Company's amended audited annual financial statement for the fiscal year ended June 30, 2020, filed October 28, 2020.

Discontinued Operations

The Company classifies a disposal group as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use. Upon classification as a discontinued operation, assets and liabilities are measured at their fair value less costs to sell.

Current assets, non-current assets, current liabilities and non-current liabilities will be presented combined on one line under assets or liabilities held for sale, respectively.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

4. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

All income or loss on discontinued operations, including any impairment charges recorded on transfer of CGU assets to conformity with IFRS 5 *Assets Held for Sale and Discontinued Operations*, are charged to one line on the statement of profit or loss.

5. DISCONTINUED OPERATIONS

Consolidated discontinued operations as at December 31, 2020 and June 30, 2020 are below:

As at	December 31, 2020		June 30, 2020	
Current				
Cash	\$	2,119,897	\$	859,306
Amounts receivable (Note 14)		889,473		673,124
Prepays		54,627		75,044
Biological assets (Note 9)		2,396,211		1,842,848
Inventory (Note 10)		3,382,556		1,090,625
	\$	8,842,764	\$	4,540,947
Non-current assets				
Deposits		796,787		1,033,234
Fixed Assets (Note 12)		4,050,187		4,048,557
Right of use asset		3,019,212		2,916,092
Investments		89,256		-
Intangible assets (Note 11)		1,035,756		2,000,631
Goodwill (Note 6)		3,346,533		7,334,212
Total non-current assets	\$	12,337,731	\$	17,332,726
				-
TOTAL ASSETS	\$	21,180,495	\$	21,873,673
LIABILITIES				
Current				
Accounts payable	\$	6,102,507	\$	3,250,511
Unearned revenue		231,957		52,063
Lease liability		951,350		1,313,386
		7,285,814		4,615,960
Long-term				
Lease liability - long term		2,117,835		2,096,778
TOTAL LIABILITIES	\$	9,403,649	\$	6,712,738
NET ASSETS	\$	11,776,846	\$	15,160,935

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

5. DISCONTINUED OPERATIONS (CONTINUED)

Loss on discontinued operations:

	For the six months ended	
	December 31, 2020	December 31, 2019
Revenue	\$ 4,904,569	\$ 5,101,988
Cost of sales	(1,888,137)	(2,823,806)
	3,016,432	2,278,182
Bio asset adjustment	69,601	1,575,506
Gross Margin	3,086,033	3,853,688
General and administrative costs	(1,387,053)	(3,899,132)
Fair value adjustment upon HFS	(3,987,679)	-
Other items	(565,432)	(488,920)
Total income (loss)	\$ (2,854,131)	\$ (534,364)
Other comprehensive loss	249,896	632,239
Comprehensive income (loss)	\$ (2,604,235)	\$ 97,875

A summary of cash flows:

	For the six months ended	
	December 31, 2020	December 31, 2019
Net income	\$ (2,854,131)	\$ (534,364)
Non-cash items	3,987,679	-
Changes in non-cash working capital	(2,041,226)	(219,859)
Cash flows from operations	(907,678)	(754,223)
Cash used in investing activities	2,168,269	(2,992,412)
Cash from financing activities	-	3,127,776
Change in cash	1,260,591	(118,859)
Cash, beginning	859,306	978,165
Cash, end	\$ 2,119,897	\$ 859,306

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

5. DISCONTINUED OPERATIONS (CONTINUED)

Project 1493

On November 11, 2020, GSRX's subsidiary, Project 1493 entered into an asset purchase agreement (the "Asset Purchase Agreement") with Puerto Rico Industrial Commercial Holdings, LLC ("PRICH") to sell and transfer all of Project 1493's operating assets in Puerto Rico in consideration for US\$743,333.33 (including Sales and Use Tax of Puerto Rico) (the "Project 1493 Asset Purchase Price"), which may be divided and credited towards the Project 1493 Asset Purchase Price as follows:

- (a) US\$133,333.33 for the purchase of medical cannabis trim;
- (b) US\$533,333.33 for the purchase of medical cannabis flower; and
- (c) US\$76,666.66 for the payment of Sales and Use Tax of Puerto Rico in respect of the purchases set out in (a) and (b) above.

Additionally, PRICH assumed all of Project 1493's liabilities in respect of the assets sold and the leases assumed. The fair value of the total consideration issued to the Company for Project 1493 was \$6,086,655.

As at	December 31, 2020		June 30, 2020	
Current				
Cash	\$	1,758,056	\$	789,500
Amounts receivable (Note 14)		363		73,455
Prepays		-		6,760
Biological assets (Note 9)		-		-
Deposit		-		-
Inventory (Note 10)		2,413,114		573,515
	\$	4,171,533	\$	1,443,230
Non-current assets				
Deposits		39,380		350,384
Fixed Assets (Note 12)		2,294,745		2,324,888
Right of use asset		1,722,328		1,413,810
Investments		89,256		-
Intangible assets (Note 11)		1,035,756		2,000,631
Goodwill (Note 6)		1,884,495		5,577,799
Total non-current assets	\$	7,065,960	\$	11,667,512
TOTAL ASSETS	\$	11,237,493	\$	13,110,742
LIABILITIES				
Current				
Accounts payable	\$	3,413,206	\$	650,875
Unearned revenue		-		-
Lease liability		480,405		720,644
		3,893,611		1,371,519
Long-term				
Lease liability - long term		1,257,227		1,236,170
TOTAL LIABILITIES	\$	5,150,838	\$	2,607,689
NET ASSETS	\$	6,086,655	\$	10,503,053

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

5. DISCONTINUED OPERATIONS (CONTINUED)

Loss on discontinued operations for Project 1493 is below:

	For the six months ended	
	December 31, 2020	December 31, 2019
Revenue	\$ 3,619,507	\$ 4,093,580
Cost of sales	(1,854,547)	(2,112,328)
	1,764,960	1,981,252
Bio asset adjustment	-	-
Gross Margin	1,764,960	1,981,252
General and administrative costs	(1,103,795)	(2,660,808)
Fair value adjustment upon HFS	(3,693,304)	-
Other items	(565,432)	(467,896)
Total income (loss)	\$ (3,597,571)	\$ (1,147,452)
Other comprehensive loss	210,304	680,420
Comprehensive income (loss)	\$ (3,387,267)	\$ (467,032)

Upon recognition as an asset held for sale, the Company recorded an impairment charge against NVPR goodwill of \$1,290,836 in accordance with IAS 36 and IFRS 5.

A summary of cash flows for Project 1493 is as follows:

	For the six months ended	
	December 31, 2020	December 31, 2019
Net income	\$ (3,597,571)	\$ (1,147,452)
Non-cash items	3,693,304	-
Changes in non-cash working capital	(1,759,747)	155,552
Cash flows from operations	(1,664,014)	(991,900)
Cash used in investing activities	2,632,570	937,788
Cash from financing activities	-	-
Change in cash	968,556	(54,112)
Cash, beginning	789,500	843,612
Cash, end	\$ 1,758,056	\$ 789,500

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

5. DISCONTINUED OPERATIONS (CONTINUED)

NVPR

On November 13, 2020, Natural Venture entered into an agreement (the “Natural Ventures Agreement”) with Puerto Rico Industrial Commercial Holdings Biotech Corp. to sell and transfer all of Natural Ventures’ operating assets in Puerto Rico in consideration for US\$4,600,000 payable as follows:

- (a) US\$550,000 upon execution and approval of the Regulatory Board of Medicinal Cannabis (Puerto Rico Department of Health) in respect of the transactions contemplated in the Natural Ventures Agreement; and
- (b) US\$4,050,000 payable in 36 installments of US\$112,500.

The completion of the sale and transfer of Natural Ventures’ operating assets in Puerto Rico to PRICH is conditional upon receiving approval and authorization of the applicable governmental authorities, including, the approval of the Regulatory Board of Medicinal Cannabis (Puerto Rico Department of Health), and satisfactory due diligence of the operating assets of Natural Ventures by PRICH.

A summary of asset and liabilities held for sale for NVPR are below:

As at	December 31, 2020		June 30, 2020	
Current				
Cash	\$	361,841	\$	69,806
Amounts receivable (Note 14)		889,110		599,669
Prepays		54,627		68,284
Biological assets (Note 9)		2,396,211		1,842,848
Deposit		-		-
Inventory (Note 10)		969,442		517,110
	\$	4,671,231	\$	3,097,717
Non-current assets				
Deposits		757,407		682,850
Fixed Assets (Note 12)		1,755,442		1,723,669
Right of use asset		1,296,884		1,502,282
Investments		-		-
Intangible assets (Note 11)		-		-
Goodwill (Note 6)		1,462,038		1,756,413
Total non-current assets	\$	5,271,771	\$	5,665,214
TOTAL ASSETS	\$	9,943,002	\$	8,762,931
LIABILITIES				
Current				
Accounts payable	\$	2,689,301	\$	2,599,636
Unearned revenue		231,957		52,063
Lease liability		470,945		592,742
		3,392,203		3,244,441
Long-term				
Lease liability - long term		860,608		860,608
TOTAL LIABILITIES	\$	4,252,811	\$	4,105,049
NET ASSETS	\$	5,690,191	\$	4,657,882

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

5. DISCONTINUED OPERATIONS (CONTINUED)

Loss on discontinued operations for NVPR is below:

	For the six months ended	
	December 31, 2020	December 31, 2019
Revenue	\$ 1,285,062	\$ 1,008,408
Cost of sales	(33,590)	(711,478)
	1,251,472	296,930
Bio asset adjustment	69,601	1,575,506
Gross Margin	1,321,073	1,872,436
General and administrative costs	(283,258)	(1,238,324)
Fair value adjustment upon HFS	(294,375)	-
Other items	-	(21,024)
Total income (loss)	\$ 743,440	\$ 613,088
Other comprehensive loss	39,592	(48,181)
Comprehensive income (loss)	\$ 783,032	\$ 564,907

Upon recognition as an asset held for sale, the Company recorded an impairment charge against NVPR goodwill of \$98,927 in accordance with IAS 36 and IFRS 5.

A summary of cash flows for NVPR is as follows:

	For the six months ended	
	December 31, 2020	December 31, 2019
Net income	\$ 743,440	\$ 613,088
Non-cash items	294,375	-
Changes in non-cash working capital	(281,479)	(375,411)
Cash flows from operations	756,336	237,677
Cash used in investing activities	(464,301)	(3,430,200)
Cash from financing activities	-	3,127,776
Change in cash	292,035	(64,747)
Cash, beginning	69,806	134,553
Cash, end	\$ 361,841	\$ 69,806

In accordance with IFRS 5, the Company determined that the sale constituted a discontinued operation as the net assets are to be expected principally through a sale transaction rather than through continual use. The sale constitutes a complete disposal of the Natural Ventures - Puerto Rico CGU and a significant disposal within the GSRX CGU (Note 6).

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

5. GOODWILL, ACQUISITIONS AND ACQUISITIONS PAYABLE

Goodwill arose over the acquisition of Natural Ventures and GSRX due to the benefit of expected revenue growth in Latin American markets and future market developments. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. None of the goodwill arising on these acquisitions are expected to be deductible for tax purposes. All acquisitions were dealt with at arm's length with non-related parties at the time of transaction.

The Company's goodwill arose on acquisitions and are summarized as follows:

GSRX Industries Inc.

	Natural Ventures		GSRX		Total
	<i>Puerto Rico</i>		<i>Puerto Rico</i>		
Net					
Balance, June 30, 2020	\$	3,557,713	\$	5,577,799	\$ 11,769,422
Transfer to Discontinued Operations (Note 5)		(3,557,713)		(5,577,799)	(11,769,422)
Balance, December 31, 2020	\$	-	\$	-	\$ -

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

6. GOODWILL, ACQUISITIONS AND ACQUISITIONS PAYABLE (CONTINUED)

During the year ended June 30, 2020, the Company acquired GSRX. The acquisition of GSRX was accounted for as a business combination as follows:

Consideration		
Fair value of initial investment in GSRX	\$	4,658,381
Common shares		10,705,358
Total consideration	\$	15,363,739
Fair value of net assets acquired		
Cash	\$	2,026,139
Accounts receivable		47,627
Inventory		689,750
Deposits		367,027
Equipment		472,310
Land		322,316
Building		1,147,069
Leasehold improvements		954,273
License		2,727,986
Right of use assets		2,912,084
Construction in progress		897,157
Investment in Chemesis		6,027,801
Total assets	\$	18,591,539
Current liabilities	\$	1,082,159
Lease liabilities		2,912,084
Total liabilities	\$	3,994,243
Net identifiable assets		14,597,296
Less: non-controlling interests portion	\$	(4,811,188)
Company's share of net assets acquired		9,786,027
Goodwill	\$	5,577,799

Goodwill arising from the acquisition represent expected synergies, future income and growth, and other intangibles that do not qualify for separate recognition. The goodwill arising on this acquisition is not expected to be deductible for tax purposes.

Caribbean Green LLC

On September 9, 2019, Natural Ventures entered into an asset acquisition agreement to acquire three dispensaries in Puerto Rico for total payments of USD \$1,200,000, due in monthly installments of USD \$50,000. The closing of the agreement is subject to the Company successfully transferring the licenses into its name. This requires approval from the Puerto Rico Department of Health. As at December 31, 2020 this has not been completed. During the year ended June 30, 2020, the Company paid USD \$450,000 (\$615,000) and is included in deposits subject to the completion of the license transfer. As at December 31, 2020, the Company has recorded advances of \$USD339,860 (\$CAD 454,054) for operating purposes which was fully allowed for and recorded as expense in the statement of loss and comprehensive loss. As at December 31, 2020, the Company recorded USD \$450,000 (\$615,000), included in assets held for sale (Note 5).

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

7. RIGHT OF USE ASSETS AND LEASE LIABILITIES

The Company's right-of-use asset relates to the lease of office space. On adoption of IFRS 16, the group recognized lease liabilities in relation to leases which had previously been classified as 'operating leases' under the principles of IAS 17 Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate as of July 1, 2019.

The weighted average lessee's incremental borrowing rate applied to the lease liabilities was 15%.

The carrying value of the Company's right of use assets is as follows:

Cost	
Balance, June 30, 2020	\$ 4,003,665
Effects of foreign exchange	625,137
Transfer to discontinued operations (Note 5)	(4,628,802)
Balance, December 31, 2020	\$ -
Accumulated depreciation	
Balance, June 30, 2020	\$ 1,087,573
Depreciation	231,131
Transfer to discontinued operations	(1,318,704)
Balance, December 31, 2020	\$ -
Balance, June 30, 2020	\$ 2,916,092
Balance, December 31, 2020	\$ -

The carrying value of the lease liabilities is as follows:

Lease liabilities	
Balance, June 30, 2020	\$ 3,410,542
Interest	219,723
Repayments	(697,873)
Effects of foreign exchange	(134,443)
Balance, transferred to discontinued operations	\$ 2,797,949

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

8. INVENTORY

All inventory consists of finished goods Cannabis products held at our California dispensary.

9. INTANGIBLE ASSETS

Cost	License rights
Balance, June 30, 2020	\$ 4,490,611
Transfer to Discontinued Operations (Note 5)	(2,727,986)
Balance, December 31, 2020	\$ 1,762,625
Accumulated amortization	
Balance, June 30, 2020	\$ (2,438,837)
Additions	(16,667)
Transfer to Discontinued Operations (Note 5)	737,355
Balance, December 31, 2020	\$ (1,728,149)
Net, June 30, 2020	\$ 2,051,774
Net, December 31, 2020	\$ 34,476

The Company's license rights are summarized as follows:

La Finca

During the year ended June 30, 2019, the Company acquired a license in La Finca for \$100,000. The remaining balance on this license after accumulated amortization is \$42,810, the balance of remaining intangible assets above.

Natural Ventures License

On November 30, 2018, the Company acquired Natural Ventures which holds a cultivation license and a cannabis manufacturing license. These licenses had a fair value of \$1,662,625 and had a useful life of one year. Due to the disposal of the US – Puerto Rico CGU subsequent to December 31, 2020, these assets were reclassified to Assets Held for Sale (Note 5).

GSRX Licenses

GSRX operated 5 cannabis dispensaries in Puerto Rico, through its wholly owned subsidiary, Project 1493, LLC. The licenses were measured at a fair value of \$2,727,986, at the acquisition date of GSRX on August 28, 2019. The licenses have a useful life of 3 to 5 years. Due to the disposal of the US – Puerto Rico CGU subsequent to December 31, 2020, these assets were reclassified to Assets Held for Sale (Note 5). \$218,207 in amortization was transferred to net loss from discontinuing operations during the six months ended December 31, 2020.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

10. NON-CONTROLLING INTERESTS

A continuity of the Company's non-controlling interests is below:

	Natural Ventures	Kieley Growth	GSRX	SAP	Total
	<i>Puerto Rico</i>	<i>United States</i>	<i>United States</i>	<i>United States</i>	
Balance, June 30, 2020	\$ 44,932	\$ 99,679	\$ 4,080,834	\$ -	\$ 4,225,445
Net loss	(989,350)	0	(3,247,002)	-	(4,236,352)
Other comprehensive loss	-	111,363	(1)	1,887	113,249
Disposal	944,418		(833,831)		110,587
Balance, December 31, 2020	\$ -	\$ 211,042	\$ -	\$ 1,887	\$ 212,929

Summarized financial information from each subsidiary with significant non-controlling interests is as follows:

	Kieley Growth	GSRX	SAP	Total
Total assets	\$ -	107,280	-	107,280
Total liabilities	126,339	242,818	12,585	381,742
		-		
Discontinued operations, net of tax	-	-	-	-
Net loss	\$ -	-	-	-

11. FIXED ASSETS

	Machinery and equipment	Leasehold improvements	Buildings	Construction in progress	Land	Total
Cost						
Balance, June 30, 2020	\$ 1,465,215	\$ 2,175,189	\$ 251,011	\$ 918,168	\$ -	\$ 4,809,583
Additions	-		-	-	-	-
Transfer	-	150,195	-	(150,195)	-	-
Transfer to assets held for sale (Note 5)	(1,299,678)	(2,325,384)	(251,011)	(767,973)	-	(4,644,046)
Balance, December 31, 2020	\$ 165,537	\$ -	\$ -	\$ -	\$ -	\$ 165,537
Depreciation						
Balance, June 30, 2019	\$ 219,540	\$ 334,793	\$ 5,358	\$ -	\$ -	\$ 559,691
Additions	29,174	-	-	-	-	29,174
Transfer to assets held for sale	(219,540)	(334,793)	(5,358)	-	-	(559,691)
Balance, December 31, 2020	\$ 29,174	\$ -	\$ -	\$ -	\$ -	\$ 29,174
Net book value						
June 30, 2020	\$ 1,245,675	\$ 1,840,396	\$ 245,653	\$ 918,168	\$ -	\$ 4,249,892
December 31, 2020	\$ 194,711	\$ -	\$ -	\$ -	\$ -	\$ 194,711

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

12. CONVERTIBLE DEBT

During the year ended June 30, 2020, the Company completed a convertible debt financing for total gross proceeds of \$1,455,080 (USD\$1,100,000). The convertible debentures bear interest at a rate of 10% per year and mature two years from the closing date. The convertible debentures are unsecured and are convertible, at the option of the holder, into common shares of the Company at a price of USD\$1.00 per common share. The debentures carry a derivative liability whereby the number of shares is fixed to the US dollar. The Company recognized a derivative liability of \$620,960 and re-measures the liability at the end of each reporting period using the Black-Scholes option pricing model.

The Company has the right to repay and cancel convertible debentures at any time prior to the maturity date at a price equal to 105% of the principal amount of the convertible debentures then outstanding plus accrued and unpaid interest thereon.

During the year ended June 30, 2019, the Company completed two tranches of convertible debt financing for total gross proceeds of \$3,500,000. The first tranche of \$2,000,000 closed on December 4, 2018 and the final tranche of \$1,500,000 closed on December 20, 2018. The convertible debentures bear interest at a rate of 8% per year and mature two years from the closing date. The convertible debentures are unsecured and are convertible, at the option of the holder, into common shares of the Company at a price of \$12.50 per common share. In addition, the Company granted one common share purchase warrant for each common share underlying the convertible debentures for a total of 280,000 warrants. Each warrant is exercisable into one common share at an exercise price of \$15.00 for a period of 24 months.

The Company has the right to repay and cancel the convertible debentures at any time prior to the maturity date at a price equal to 105% of the principal amount of the convertible debentures then outstanding plus accrued and unpaid interest thereon. In addition, the Company has the right to compel the conversion of the convertible debentures in the event that the daily volume weighted average trading price of the common shares exceeds \$2.50 per common share for 10 consecutive trading days. The Company recognized a derivative liability of \$1,079,782 relating to the first tranche closed on December 4, 2018 and a derivative liability of \$692,013 on the second tranche closed on December 20, 2018 and re-measures the liability at the end of each reporting period using the Black-Scholes option pricing model. There was no residual value allocated to the warrants attached to the debentures.

On October 6, 2020, the Company settled \$250,000 on its 2018 convertible debenture (Note 14).

As at December 31, 2020 and June 30, 2020, the fair value of the Company's derivative liability was \$nil.

The following table summarizes the Company's convertible debt:

Balance, June 30, 2020	\$	1,063,551
Accretion and interest		109,486
Settlement		(250,000)
Foreign exchange		(6,792)
Balance, December 31, 2020	\$	916,245

Subsequent to December 31, 2020, the Company issued 1,912,106 common shares to settle \$617,723 in convertible debentures outstanding. No gain or loss was recorded on the issuance.

13. AMOUNTS RECEIVABLE

Amounts receivable consist of Canadian GST receivables. As of December 31, 2020, the Company recorded an allowance for doubtful accounts of \$nil (June 30, 2020 - \$728,274). If circumstances related to specific customers and related parties change, estimates of the recoverability of amounts receivable could also change.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

14. SHAREHOLDERS' EQUITY

14.1 Authorized share capital

Unlimited number of common shares with no par value.

Effective December 20, 2019, the Company completed a share consolidation of its share capital on the basis of ten existing common shares for one new common share. All common share and per share amounts in these consolidated financial statements are retroactively presented on a post-share consolidation basis, including the number and exercise price of all share options and warrants.

As at December 31, 2020, 688,072 common shares were held in escrow.

14.2 Issued share capital

Common shares issued and outstanding as at December 31, 2020 are 40,906,091, of which 729,187 common shares are classified as held internally and deducted from the consolidated statement of changes in equity.

- i) On November 20, 2020, the Company issued 63,313 with a fair value of \$22,223 to settle the same amount in liabilities with an arm's length third party.
- ii) Further, on November 20, 2020, the Company issued 250,000 shares with a fair value of \$87,750 pursuant to a settlement and termination agreement with GEM Financial (Note 20).
- iii) During the six months ended December 31, 2020, the Company issued 2,573,431 common shares pursuant to warrant exercises for proceeds of \$1,042,000.

Subsequent to December 31, 2020, a further 4,257,523 common shares were issued pursuant to warrants exercises for proceeds of \$1,902,297.

14.3 Warrants

As of December 31, 2020, the following warrants were outstanding:

	Warrants	Exercise Price
June 30, 2020	21,523,680	\$ 3.48
Issued	3,305,216	0.97
Cancelled/Expired	(280,010)	(15.00)
Exercised	(2,573,431)	0.41
December 31, 2020	21,975,455	\$ 1.18

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

14. SHAREHOLDERS' EQUITY (CONTINUED)

14.3 Warrants (continued)

As of June 30, 2020, the following warrants were outstanding:

Expiry date	Warrants	Exercise Price
December 20, 2023	31,250	15.00
January 21, 2024	38,460	24.50
March 3, 2022	150,000	25.00
April 22, 2024	18,918	25.00
May 8, 2024	18,900	25.00
May 30, 2024	37,837	25.00
June 13, 2024	5,405	25.00
September 18, 2021	54,053	15.00
January 21, 2022	13,820,013	0.41
January 23, 2022	570,192	0.70
January 23, 2022	1,232,711	1.12
May 19, 2022	1,420,000	1.00
May 20, 2022	1,272,500	1.00
July 3, 2022	2,612,800	1.00
July 24, 2022	692,416	0.85
Balance, December 31, 2020	21,975,455	\$ 1.02

As at December 31, 2020, the weighted-average remaining life of the outstanding warrants was 0.97 years (June 30, 2020 – 2.37).

Subsequent to December 31, 2020, a further 4,257,523 warrants were exercised for proceeds of \$1,902,297.

14.4 Options and share-based compensation

The Company has adopted a stock option plan whereby up to 10% of the outstanding shares of the Company as of the date of grant have been reserved for the grant and issuance to its employees, officers, directors and consultants. Under the plan, the exercise price of an option may not be set at less than the minimum price permitted by the CSE. The aggregate number of options granted to any one individual during any 12-month period may not exceed 5% of the issued shares of the Company, or 2% in the case of consultants and investor relations representatives. The stock option plan provides for full vesting of the stock options on the date of approval of the options by the appropriate regulatory authority. Stock options granted to any person engaged in investor relations activities will vest over a period of not less than 12 months with no more than 25% of the stock options vesting in any six-month period. The exercise price of any stock options granted under the plan shall be determined by the Board but may not be less than the market price of the common shares on the Exchange on the date of grant (less any discount permissible under Exchange rules). The term of any stock options granted under the plan shall be determined by the Board at the time of grant but may not exceed ten years.

As at December 31, 2020, 2,295,000 stock options were outstanding, which the weighted average remaining life of the outstanding options was 4.04 years (June 30, 2020 - 4.53), expiring on January 12, 2025 at an exercise price of \$0.90. During the six months ended December 31, 2020, 430,000 of these options were cancelled. As such, 1,865,000 options were outstanding as at December 31, 2020.

Subsequent to December 31, 2020, the Company granted 1,500,000 stock options to directors, officers and consultants of the Company. These options allow the holder to exercise into one common share of the Company at a price of USD\$0.70 for a period of 5 years.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

14. SHAREHOLDERS' EQUITY (CONTINUED)

14.5 Restricted Share Rights ("RSR")

As at December 31, 2020, the Company has 2,375,000 RSRs outstanding and exercisable.

The Company's RSRs allow the holder to convert one RSR into one common share of the Company at the holder's election.

Subsequent to December 31, 2020, the Company granted 1,500,000 restricted share units to directors, officers and consultants of the Company. These RSRs vest 50% on April 13, 2021 with the balance vesting on June 13, 2021.

15. RELATED PARTY TRANSACTIONS AND BALANCES

Key management personnel are the directors and officers of the Company. Management compensation transactions for the six months ended December 31, 2020 and 2019 is summarized as follows:

	2020	2019
Management fees	\$ 518,250	\$ 225,643
Share-based payments	-	-
Total	\$ 518,250	\$ 225,643

As at December 31, 2020, \$359,658 (June 30, 2020 - \$49,875) is owed to directors and officers of the Company for unpaid fees and expenses paid on behalf of the Company.

During the six months ended December 31, 2020, the Company accrued \$162,000 (2019 - \$72,000) included in management fees to the CEO and Director of the Company pursuant to CEO and director services provided.

During the six months ended December 31, 2020, the Company accrued \$75,000 (2019 - \$60,000) included in management fees to the CFO of the Company pursuant to CFO services provided, included in accounts payable and accrued liabilities.

During the six months ended December 31, 2020, the Company accrued \$162,000 (2019 - \$75,000) included in management fees to a director of the Company pursuant to director services provided, included in accounts payable and accrued liabilities.

During the six months ended December 31, 2020, the Company paid \$18,000 (2019 - \$18,000) included in consulting fees to the Corporate Secretary and Director and of the Company pursuant to corporate secretary and director services provided.

During the six months ended December 31, 2020, the Company accrued \$101,250 (2019 - \$nil) included in consulting fees to the President and Director and of the Company pursuant to related services provided.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

16. GENERAL AND ADMINISTRATION

General and administrative costs during the six months ended December 31 are as follows:

	2020	2019
Advertising and marketing	\$ 1,755,405	\$ 434,139
Bad debt expense (Note 13)	-	216,527
Consulting and payroll (Note 17)	118,563	443,778
Finders' fee	35,000	-
Management fees (Note 17)	518,250	225,643
Office and miscellaneous	72,717	1,431,151
Professional fees	641,527	869,351
Rent	30,000	60,000
Security	-	84,251
Transfer agent and filing fees	81,410	66,938
Travel	11,891	300,709
	\$ 3,264,763	\$ 4,132,487

17. NON-CASH INVESTING AND FINANCING ACTIVITIES

See the following for non-cash note disclosures:

- i) Assets and Liabilities Held for Sale (Note 5)
- ii) Investment in GSRX (Note 6)
- iii) Right of use asset included in leases (Note 7)

18. RISK MANAGEMENT

18.1 Financial risk management

The Company may be exposed to risks of varying degrees of significance which could affect its ability to achieve its strategic objectives. The main objectives of the Company's risk management processes are to ensure that risks are properly identified and that the capital base is adequate in relation to those risks. The principal risks to which the Company is exposed are described below.

a. Capital risk

The Company manages its capital to ensure that there are adequate capital resources for the Company to maintain operations. The capital structure of the Company consists of cash and share capital.

b. Credit risk

Credit risk is the risk that a counter party will be unable to pay any amounts owed to the Company. Management's assessment of the Company's exposure to credit risk is low. The maximum amount exposed to credit risk is equal to trade receivables (see Note 14).

c. Liquidity risk

Liquidity risk is the risk that the Company is not able to meet its financial obligations as they fall due. As at December 31, 2020, the Company's working capital deficiency of \$2,652,624. The Company plans to seek additional financing through debt or equity offerings, but there can be no assurance that such financing will be available on terms acceptable to the Company or at all. Any equity offering will result in dilution to the ownership interests of the Company's shareholders and may result in dilution to the value of such interests.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

18. RISK MANAGEMENT (CONTINUED)

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due.

Contractual undiscounted cash flow requirements for contractual obligations as at December 31, 2020 are as follows:

	Less Than 1 Year \$	Years 2 and 3 \$	Years 4 and 5 \$	More Than 5 Years \$	Total \$
Accounts payable and accrued liabilities	2,078,490	-	-	-	-
Convertible debt (Note 12)	997,270	-	-	-	-

d. Market risk

Market risk incorporates a range of risks. Movements in risk factors, such as market price risk and currency risk, affect the fair values of financial assets and liabilities. The Company does not have a practice of trading derivatives

Foreign currency risk

The Company's foreign exchange risk arises from transactions denominated in other currencies.

18.2 Fair values

The carrying values of trade receivables and accounts payable and accrued liabilities approximate their fair values due to their short-term to maturity. The carrying value of convertible debt approximates its fair value based on current market rates.

Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 – Quoted prices in markets that are not active, or inputs that are not observable, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

As at June 30, 2020 and 2019 the Company held the following measured at their stated fair value hierarchy level:

	December 31, 2020		June 30, 2020	
<i>Level 1</i>				
Cash	\$	230,199	\$	185,279

During the six months ended December 31, 2020 and 2019, there were no transfers between Level 1 and Level 2 fair value measurements and there were no transfers in and out of Level 3 fair value measurements.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

19. MANAGEMENT OF CAPITAL

The Company defines the capital that it manages as its cash and share capital.

The Company's objective when managing capital is to maintain corporate and administrative functions necessary to support the Company's operations and corporate functions; and to seek out and acquire new projects of merit.

The Company manages its capital structure in a manner that provides sufficient funding for operational and capital expenditure activities. Funds are secured, when necessary, through debt funding or equity capital raised by means of private placements. There can be no assurances that the Company will be able to obtain debt or equity capital in the case of working capital deficits.

20. EQUITY FUNDING FACILITIES

On August 8, 2018, the Company entered into an equity financing agreement for up to \$25,000,000, a New York-based private equity firm.

The agreement details the purchase of up to \$25,000,000 of units of the Company, consisting of one common share and one common share purchase warrant, at discounts ranging from 15% to 25% of the market price of the Company's shares, with each equity financing occurring exclusively at the option of the Company, throughout the 24-month term of the agreement. The exercise price of the warrants will be at a 50% premium over the market price of the shares at the date of any funding loaned. There are no upfront fees or interest associated with the use of this financing. As of September 30/December 31, 2020, the Company has drawn down \$750,000 (2019 2020 - \$750,000) on the equity financing arrangement. Either party to this agreement has the right to terminate this agreement by providing ten business days written notice to the other party of its intention to do so.

On November 17, 2020, the Company entered into a settlement and termination agreement, whereby the Company issued 250,000 shares measured at a value of USD \$0.26 per share and paid \$75,000 as consideration for terminating the agreement with GEM. See Note 14.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

21. SEGMENTED INFORMATION

The Company currently has four operating segments and generates external revenues from the sale of cannabis products. The operating segments have been disclosed by geographical region as follows:

	Assets \$	Liabilities \$	Revenues \$	Depreciation \$	Interest \$	Income tax recovery \$	Profit (loss) \$
Canada	466,250	2,570,722	-	23,292	(116,175)	-	(2,877,136)
United States - California		235,490					
United States - Puerto Rico <i>Discontinued operations</i> – NVPR	-	-	1,285,062	287,549	15,768	-	(4,946,751)
<i>Discontinued operations</i> – Project 1493	-	-	3,619,507	402,054	158,465	-	(9,632,163)
Columbia	107,280	190,755	-	-	-	-	-
	573,530	2,996,967	4,904,569	712,895	58,058	-	(17,456,050)

**Revenues, interest and depreciation for the six months ended December 31, 2020 are included in loss from discontinued operations (Note 5).*

The Company's reportable segments are organized by geographic regions and by nature of operations which include: Canada, US-California, Columbia and discontinued operations pursuant to the sale during the period of the Company's US-Puerto Rico cultivation and manufacturing and US-Puerto Rico dispensaries.

Canada is the parent company with operations focused on governance and assets consisting of equipment. US-California revenues consists of manufacturing and extraction of THC oil sold to dispensaries. The assets of California were written off during the year ended June 30, 2020, as the market has taken a significant downturn.

Segmented disclosure above is presented in the same manner than management evaluates performance, net of intercompany eliminations. There were no such intercompany transactions during the period.

Chemesis International Inc.
Notes to the Condensed Consolidated Interim Financial Statements
As at and for the three and six months ended December 31, 2020 and 2019
(Expressed in Canadian dollars)

22. RESTATEMENT

During the preparation of the 2020 year-end consolidated financial statements the Company identified an error in the accounting treatment of the convertible debentures issued in the fiscal 2019 period. The Company identified there was a clause that allowed for the number of shares to be converted was not fixed thereby resulting in an embedded derivative that was required to be accounted for as at FVTPL. These adjustments, cumulatively, impacted the consolidated statement of financial position as at June 30, 2019 and the consolidated statement of loss and comprehensive loss. These restatements resulted in no change to other comprehensive income nor earnings per share.

The table below summarizes the impact of the restated consolidated financial statements for December 31, 2019:

INCOME STATEMENT	As previously reported	Restatement	Restated, December 31, 2019
Fair value change of derivative liability	\$ -	\$ -	-
Interest - convertible debenture	\$ 290,364	\$ (222,164)	\$ 68,200
STATEMENT OF FINANCIAL POSITION			
Derivative Liability	\$ -	\$ (361,322)	\$ (361,322)
Convertible debt	(4,941,107)	351,151	(4,589,956)
Contributed Surplus	(506,145)	(211,993)	(718,138)
Deficit	(58,199,356)	222,164	(57,977,192)

22. SUBSEQUENT EVENTS

- i) On January 12, 2021, the Company granted 1,500,000 options at an exercise price of USD\$0.70 expiring in 5 years to directors, officers and consultants;
- ii) On January 12, 2021, the Company granted 1,500,000 RSRs to directors, officers and consultants of the Company. The RSRs vest 50% over a period of three months with the balance vesting after six months;
- iii) On January 18, 2021, the Company issued 3,687,419 units at a price of \$.325 (USD\$0.255) for proceeds of CAD\$1,200,000. Each unit consists of one common share and one share purchase warrant exercisable at USD\$0.34 for two years;
- iv) On January 18, 2021, the Company issued 1,912,106 common shares to settle \$619,723 in convertible debentures outstanding. See Note 12;
- v) On January 19, 2021, the Company issued 939,385 common shares to settle USD\$648,175 of accounts payable and accrued liabilities. No gain or loss was recorded on the transaction; and
- vi) On January 19, 2021, the Company issued 33,257 to settle USD\$21,950 of accounts payable and accrued liabilities with a third party.

Further, the Company issued shares pursuant to warrant exercises as follows:

Expiry date	Number of warrants exercised	Exercise price
January 21, 2022	3,857,523	\$0.405
January 23, 2022	200,000	\$0.70
May 19, 2022	200,000	\$1.00